

1 **Epithelial control of colonisation by *Streptococcus pneumoniae* at the human**  
2 **mucosal surface**

3

4 Caroline M Weight<sup>1</sup>, Cristina Venturini<sup>1</sup>, Sherin Pojar<sup>2</sup>, Simon P. Jochems<sup>2</sup>, Jesús Reiné<sup>2</sup>,  
5 Elissavet Nikolaou<sup>2</sup>, Carla Solorzano<sup>2</sup>, Carl Anderson<sup>3</sup>, Mahdad Noursadeghi<sup>1</sup>, Jeremy S  
6 Brown<sup>4</sup>, Daniela M. Ferreira<sup>2</sup>, Robert S Heyderman<sup>1</sup>

7

8 <sup>1</sup>Division of Infection and Immunity, University College London, London, United Kingdom,  
9 <sup>2</sup>Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United  
10 Kingdom, <sup>3</sup>Wellcome Sanger Institute, Hinxton, <sup>4</sup>Department of Respiratory Medicine,  
11 University College London, London, United Kingdom

12

13 Corresponding Author: Dr Caroline M. Weight, Division of Infection and Immunity,  
14 Cruciform Building, Gower Street, University College London, WC1E 6BT, UK. Email:  
15 [c.weight@ucl.ac.uk](mailto:c.weight@ucl.ac.uk); Tel: 02031082127

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36 **Abstract**

37 Control of *Streptococcus pneumoniae* colonisation at human mucosal surfaces is critical to  
38 reducing the burden of pneumonia and invasive disease, interrupting onward transmission,  
39 and in achieving herd protection. We hypothesised that the pattern of pneumococcal-  
40 epithelial engagement dictates the inflammatory response to colonisation, and that this  
41 epithelial sensing is linked to bacterial clearance. Here we have used nasal curette biopsies  
42 from a serotype 6B Experimental Human Pneumococcal Carriage Model (EHPC) to  
43 visualize *S. pneumoniae* colonisation and relate these interactions to epithelial surface  
44 marker expression and transcriptomic profile upregulation. We have used a Detroit 562 cell  
45 co-culture model to further understand these processes and develop an integrated epithelial  
46 transcriptomic module to interrogate gene expression in the EHPC model. We have shown  
47 for the first time that pneumococcal colonisation in humans is characterised by microcolony  
48 formation at the epithelial surface, microinvasion, cell junction protein association, epithelial  
49 sensing, and both epithelial endocytosis and paracellular transmigration. Comparisons with  
50 other clinical strains *in vitro* has revealed that the degree of pneumococcal epithelial surface  
51 adherence and microinvasion determines the host cell surface marker expression (ICAM-1  
52 and CD107), cytokine production (IL-6, IL-8 and ICAM-1) and the transcriptomic response.  
53 In the context of retained barrier function, epithelial microinvasion is associated with the  
54 upregulation of a wide range of epithelial innate signalling and regulatory pathways,  
55 inflammatory mediators, adhesion molecules, cellular metabolism and stress response  
56 genes. The prominence of epithelial TLR4R signalling pathways implicates pneumolysin, a  
57 key virulence factor, but although pneumolysin gene deletion partially ameliorates the  
58 inflammatory transcriptional response *in vitro*, critical inflammatory pathways persist in  
59 association with enhanced epithelial adhesion and microinvasion. Importantly, the pattern  
60 of the host-bacterial interaction seen with the 6B strain *in vitro* is also reflected in the EHPC  
61 model, with evidence of microinvasion and a relatively silent epithelial transcriptomic profile

62 that becomes most prominent around the time of bacterial clearance. Together these data  
63 suggest that epithelial sensing of the pneumococcus during colonisation in humans is  
64 enhanced by microinvasion, resulting in innate epithelial responses that are associated with  
65 bacterial clearance.

66

## 67 **Keywords**

68 *Streptococcus pneumoniae*, mucosa, Innate cell response, Epithelial cells, host-pathogen  
69 interactions, Human Challenge Model, RNA sequencing

70

## 71 **Highlights**

72

- 73 • Colonisation of the human mucosa by *Streptococcus pneumoniae* is associated with  
74 microcolony formation, microinvasion, epithelial sensing and an epithelial innate  
75 response.
- 76 • Following adherence to the epithelial cell surface, microinvasion of the epithelium  
77 may occur by endocytosis and/or lateral migration between cells without necessarily  
78 compromising barrier integrity.
- 79 • The pattern of pneumococcal epithelial surface adherence and microinvasion  
80 determines the host cell response through a range of innate signaling and regulatory  
81 pathways, inflammatory mediators, adhesion molecules, cellular metabolism and  
82 stress response genes.
- 83 • Epithelial sensing is triggered by, but not wholly dependent on pneumolysin, a key  
84 virulence factor of *S. pneumoniae*.

85

86

## 87 **Introduction**

88

89 Colonisation of upper respiratory tract (URT) mucosa by a range of bacteria is a necessary precursor  
90 to transmission and disease. *Streptococcus pneumoniae* is a common coloniser of the human  
91 nasopharynx and is estimated to be responsible for >500,000 deaths due to pneumonia, meningitis  
92 and bacteraemia in children aged 1–59 months worldwide<sup>1</sup>. In comparison to gut pathogen-mucosal  
93 interactions<sup>2</sup>, the control of pneumococcal colonisation is far less well understood, particularly in  
94 humans<sup>3</sup>.

95

96 In Europe and North America, there has been a dramatic impact of pneumococcal conjugate vaccine  
97 (PCV) on vaccine serotype (VT) invasive disease and carriage<sup>4,5</sup>. Indeed, more than 50% of PCV  
98 impact has been due to a reduction in VT colonisation resulting in reduced transmission and  
99 therefore disease. This is the basis of herd protection<sup>4,5</sup>. However, the emergence of non-VT  
100 pneumococcal disease across the world and the more modest impact of PCV on colonisation in high  
101 transmission settings threaten this success<sup>6-10</sup>. As a first step towards further optimising vaccine  
102 impact on pneumococcal colonisation, it is critically important to define the mechanistic basis of the  
103 control of *S. pneumoniae* at the mucosal surface.

104

105 We and others have previously demonstrated that antigen-specific URT mucosal T cell immune  
106 memory to subcapsular pneumococcal protein antigens in humans is acquired with age in humans,  
107 is predominately pro-inflammatory and is heavily regulated by Treg<sup>11-13</sup>. Antibodies to subcapsular  
108 protein antigens rather than to the polysaccharide capsule (the target of currently licenced vaccines),  
109 also appear important for the natural control of colonisation and clearance<sup>14</sup>. We and others<sup>15,16</sup>,  
110 suggest that the URT epithelium is at the centre of this process, orchestrating both  
111 innate/inflammatory and adaptive immune mechanisms<sup>17-19</sup>, promoting bacterial clearance. The  
112 epithelium senses bacteria colonising the mucosal surface, rapidly transducing inflammatory signals  
113 and recruiting immune cells. However, murine models<sup>20</sup> and epidemiological studies of viral-

114 coinfection<sup>21,22</sup> suggest that the resulting inflammation also leads to onward transmission to  
115 susceptible individuals<sup>23</sup>. This inflammation-driven transmission is crucial for the continued success  
116 of the pneumococcus.

117

118 Nasal colonisation by *S. pneumoniae* in murine models is proinflammatory<sup>24</sup> and is associated with  
119 epithelial paracellular transmigration and tight junction modulation<sup>25</sup>. Mediated through  
120 pneumococcal protein C (PspC)–polymeric immunoglobulin receptor (pIgR) interactions<sup>26,27</sup>, *S.*  
121 *pneumoniae* invasion of immortalised epithelial cell monolayers has also been shown to occur by  
122 endocytosis<sup>27</sup>. The relative importance of epithelial endocytosis and paracellular migration in  
123 microinvasion remains uncertain<sup>27</sup> but may influence epithelial sensing of this otherwise extracellular  
124 pathogen through multiple pathogen-associated molecular patterns (PAMPS). These may include  
125 TLR2 signalling via lipoteichoic acid<sup>28</sup>, Nod1 signalling via peptidoglycan<sup>29</sup> and TLR4 signalling via  
126 pneumolysin<sup>23,30</sup>, a pore-forming toxin that mediates transmission in an infant mouse model<sup>23,30</sup>.  
127 Indeed, microinvasion of the epithelium may overcome the sequestering of pattern recognition  
128 receptors either at the basolateral surface or intracellularly<sup>31-33</sup>.

129

130 Much of what we understand of the control of pneumococcal colonisation is derived from  
131 epidemiological studies and murine carriage models. Experimental human pneumococcal challenge  
132 (EHPC) model provides a well-controlled, reproducible tool to characterise the cellular and molecular  
133 mechanisms that underlie pneumococcal colonisation in humans<sup>34</sup>. We have therefore explored the  
134 hypothesis that epithelial microinvasion by *S. pneumoniae* enhances the innate immune responses  
135 associated with colonisation and have characterised the underlying cellular and molecular  
136 mechanism. Here, we show that pneumococcal colonisation in humans is characterised by  
137 microcolony formation and junctional protein association, epithelial sensing that is indeed enhanced  
138 by microinvasion. This occurs both by epithelial endocytosis and paracellular migration resulting in  
139 epithelial innate responses that are not entirely pneumolysin dependent and that is associated with  
140 bacterial clearance. These data implicate epithelial microinvasion in the initiation of bacterial  
141 clearance which to the benefit of the colonising pathogen may also enhance transmission.

142

143 **Methods**

144

145 **Bacteria**

146 *S. pneumoniae* clinical strains used were 6B (BHN 418<sup>35</sup>), 23F (P1121<sup>36</sup>) and TIGR4  
147 (P1672<sup>37</sup>), together with a pneumolysin deficient TIGR4 mutant strain (kind gift from Prof T  
148 Mitchell, University of Birmingham). Stocks of bacterial aliquots grown to O.D 0.3 were  
149 stored at -80°C, defrosted, resuspended in cell culture media and used once. Colony forming  
150 units were counted on horse blood agar plates (EO Labs).

151

152 **Experimental Human Pneumococcal Carriage Model (EHPC)**

153 Following written informed consent, healthy non-smoking adults between the ages of 18 –  
154 59 were inoculated with 80,000 CFU live 6B *S. pneumoniae* (BHN418), grown to mid-log  
155 phase in vegetone broth as previously described<sup>38</sup>. All volunteers were negative for the  
156 pneumococcus at baseline. Nasal washes and mucosal cells (curette biopsy) from the  
157 inferior turbinate were obtained by PBS syringe and curettage using a plastic Rhino-probe™  
158 (Arlington Scientific, Springville, UT), respectively before pneumococcal inoculation. These  
159 were then repeated on days 2, 6, 9, 14 - 27 post inoculation<sup>39</sup>. Bacteria collected from nasal  
160 washes were quantified by CFU counts. Two curettage samples were obtained and  
161 processed for confocal immunofluorescence, flow cytometry, primary cell culture and /or  
162 transcriptomic analysis by RNAseq.

163

164 Ethical approval was given by NHS Research and Ethics Committee (REC)/Liverpool School  
165 of Tropical Medicine (LSTM) REC, reference numbers: 15/NW/0146 and 14/NW/1460 and  
166 Human Tissue Authority licensing number 12548.

167

168

## 169 **Human Respiratory Tract Epithelial Cells**

170 Human pharyngeal carcinoma Detroit 562 epithelial cells (ATCC\_CCL-138) and human  
171 bronchial carcinoma Calu3 epithelial cells (ATCC\_HTB-55) were grown in 10% FCS in alpha  
172 MEM media (Gibco). Human alveolar epithelial carcinoma A549 epithelial cells  
173 (ATCC\_CCL-185) were grown in 10% FCS with 1% L-glutamine in Hams/F-12 media  
174 (Gibco).

175

## 176 **Pneumococcal-epithelial cell co-culture**

177 *Association and Invasion assays* - confluent Detroit 562 (day 8 post plating), Calu3 (day 10  
178 post plating) and A549 (day 4 post plating) monolayers were cultured on 12 well plates  
179 (Corning) were exposed to *S. pneumoniae* for three hours in 1% FCS alpha MEM. The  
180 medium was removed and cells washed three times in HBSS<sup>+/+</sup>. Cells were incubated in 1%  
181 saponin for 10 minutes at 37°C and lysed by repetitive pipetting. Dilutions of bacteria were  
182 plated on blood agar and colonies counted after 16 hours. To quantify internalised bacteria,  
183 100µg/ml gentamicin was added for 1 hour to the cells, which were then washed another  
184 three times, before incubating with Saponin and plating on blood agar plates. Colony forming  
185 units (CFU) were counted after 16 hours incubation at 37°C, 5% CO<sub>2</sub>. There were no  
186 differences in pneumococcal pre- or post-inoculum, or density between the strains, in the  
187 cell supernatant three hours post-infection.

188 *Transmigration assay* - Detroit 562 cells were cultured on 3µm pore, PET Transwell Inserts  
189 (ThermoFisher) for 10 days to achieve confluent, polarised monolayers. Calu3 cells were  
190 plated onto Transwell inserts for 12 days and A549 cells for 6 days. Cell culture media was  
191 changed 1 hour prior to addition of bacteria to 1% FCS (250µl apical chamber, 1ml basal  
192 chamber). Resistance was recorded before and after *S. pneumoniae* were added using an  
193 EVOM2 (World Precision Instruments). 1mg/ml FITC-dextran (Sigma Aldrich) was added to  
194 the apical chamber of selected inserts to assess permeability. Approximately 12 million (±

195  $5.7 \times 10^6$ ) bacteria were added to the cells (~MOI 1 cell : 25 bacteria). During the time course,  
196 50 $\mu$ l was removed, diluted and plated, from the basal chamber to measure bacterial load by  
197 counting CFU/well. Permeability was recorded using a FLUOstar Omega (BMG Labtech) at  
198 488nm.

199 *Inhibition assays* - Detroit 562 cells cultured on 12 well plates were treated with 80 $\mu$ M  
200 Dynasore (Cambridge Biosciences) and 7.5 $\mu$ g/ml Nystatin (Sigma Aldrich) to block  
201 endocytosis; or 1 $\mu$ M Cytochalasin D (Bio Techne Ltd) to block actin polymerisation, for 30  
202 minutes prior to, and for the duration of pneumococcal infection incubation period. DMSO  
203 was used as a control. Cells were washed and treated with gentamicin and lysed in saponin  
204 as described above.

205

## 206 **Confocal Microscopy**

207 For the *in vivo* analysis, mucosal cells derived by curettage from the EHPC model were  
208 placed directly into 4% PFA for 1 hour. Cells were cytospun onto microscope slides and  
209 allowed to air dry. For the *in vitro* analysis, epithelial cell lines on transwell membranes were  
210 fixed in either 4% PFA (Pierce, Methanol Free) or 1:1 mix of methanol:acetone for 20  
211 minutes. Cells were permeabilised with 0.2% Triton X-100 for 10 minutes and blocked for 1  
212 hour in blocking buffer (3% goat serum and 3% BSA in PBS) before incubation with anti-6B  
213 pneumococcal antisera, JAM-A, Claudin 4 or  $\beta$  catenin primary antibodies (see  
214 Supplementary Information) for one hour and then secondary and/or conjugated antibodies  
215 for 45 minutes. DAPI solution was added for 5 minutes. After washing, the stained samples  
216 were mounted using Aqua PolyMount (VWR International) with a coverslip onto a microslide.  
217 The entire cytospin for each sample was manually viewed by microscopy for detection of  
218 pneumococci. Multiple fields of view were imaged for each transwell insert, for each  
219 condition. Images were captured using either an inverted LSM 700, LSM 880, or



220 TissueFAXS Zeiss Confocal Microscope. Z stacks were recorded at 1 $\mu$ m intervals at either  
221 40x oil or 63x oil objectives.

222

### 223 **Flow cytometry**

224 For the *in vivo* analysis, two nasal scrapes were used per sample. Cells on rhinoprobes  
225 incubated in cold PBS++ (PBS supplemented with 5mM EDTA and 0.5% FCS) were  
226 dislodged by pipetting and centrifuged at 440g for 5 mins at 4°C. Supernatant was removed  
227 and cells resuspended in 25 $\mu$ l of PBS with Live/Dead™ Fixable Violet Dead Cell Stain  
228 (ThermoFisher). After 15 minutes incubation on ice, antibody cocktail (see Supplementary  
229 Information) was added and incubated for another 15 minutes. 500 $\mu$ l of PBS++ was added  
230 to a 70 $\mu$ m filter before vortexing the samples and adding 3.5mls of PBS and filtering over  
231 the wet filter. Samples were transferred to a 5ml FACS tube, centrifuged and resuspended  
232 in 200 $\mu$ l Cell Fix (BD Biosciences). Samples were acquired on LSRII Flow Cytometer (BD  
233 Biosciences). Analyses of data was performed on the gated epithelial cell population and  
234 only samples containing 500 or more cells were considered for interpretation.

235 For the *in vitro* analysis, confluent monolayers of Detroit 562 cells on 6 well plates were  
236 incubated with *S. pneumoniae* for 6 hours in 1% FCS phenol free alpha MEM (base media,  
237 Life Technologies). Cells were washed three times in PBS and gently lifted from the plate  
238 using a cell scraper in 300 $\mu$ l of base media supplemented with 1mM EDTA. Samples were  
239 transferred to 5ml FACS tubes and placed on ice for the duration of the protocol. Each cell  
240 sample was incubated with an antibody cocktail (see supplemental information) were added  
241 to the cells for 30 minutes before rinsing in 1ml base media and centrifuging at 300g for 5  
242 minutes at 4°C. Cells were fixed in 600 $\mu$ l of 4% PFA and run through LSR II Flow Cytometer  
243 (BD Biosciences). Compensation was run and applied for each experimental replicate and  
244 voltages consistent throughout. Isotype controls (BD Biosciences), FL-1 and single stains

245 were also run for each experiment. Samples were acquired until 300,000 events had been  
246 collected. Analyses was performed using FlowJo version 10 software.

247

## 248 **ELISAs**

249 Supernatant from Detroit 562 cells that had been incubated with *S. pneumoniae* for 6 hours,  
250 was collected for cytokine analysis. IL-1beta, IL-6, IL-8, IFNg, TNFa, ICAM-1 DuoSet®  
251 ELISA kits were purchased from R&D Systems and protocol followed according to  
252 manufacturers' instructions.

253

## 254 **RNA samples and sequencing (RNASeq)**

255 Mucosal curettage samples and epithelial cell cultures (incubated with or without *S.*  
256 *pneumoniae* for 3 hours) were collected in RNALater (ThermoFisher) at -80C until  
257 extraction. Extraction was performed using the RNEasy micro kit (Qiagen) with on column  
258 DNA digestion. RNA was treated for DNA using Turbo DNA-free Kit (Qiagen) and cleaned  
259 using RNEasy Micro kit (Qiagen). Extracted RNA quality was assessed and quantified using  
260 a BioAnalyser (Agilent 2100). Library preparation and RNA-sequencing (Illumina  
261 Hiseq4000, 20M reads, 100 paired-end reads) were performed at the Beijing Genome  
262 Institute (China) or the Sanger Institute for mucosal curettage samples. *In vitro* samples  
263 used the KAPA Stranded mRNA-Seq Kit (Roche Diagnostics) to construct stranded mRNA-  
264 seq libraries from 500 ng intact total RNA after which paired-end sequencing was carried  
265 out using a 75-cycle high-output kit on the NextSeq 500 desktop sequencer (Illumina  
266 Platform, performed by the PGU, UCL).

267

268 Paired end reads were mapped to the Ensembl human transcriptome reference sequence  
269 (homo sapiens GRCh38, latest version). Mapping and generation of read counts per  
270 transcript were performed using Kallisto<sup>40</sup>, based on pseudoalignment. R/Bioconductor

271 package tximport was used to import the mapped counts data and summarise the  
272 transcripts-level data into gene level<sup>41</sup>. Further analyses were run using DESeq2 and the  
273 SARTools packages<sup>42</sup>. Normalisation and differential analyses were run using DESeq2 by  
274 use of a negative binomial generalised linear model. The estimates of dispersion and  
275 logarithmic fold changes incorporate data-driven prior distributions. SARTools, which is an  
276 R pipeline based on DESeq2, was used to generate lists of differentially expressed genes  
277 and diagnostic plots for quality control. Using these techniques, cells exposed to different *S.*  
278 *pneumoniae* strains were compared against non-infected control cells, and extracted a result  
279 table with log<sub>2</sub>fold changes, Wald test p values and adjusted p values (according to false  
280 discovery rate, FDR).

281

282 Pathways and networks analyses were performed using XGR R package<sup>43</sup>. For each strain  
283 genes that were upregulated compared to the non-infected samples with an adjusted p-  
284 value (FDR) < 0.05 were selected. Network analyses were performed using as nodes the  
285 upregulated genes labelled with significance (FDR). Four gene subnetworks were generated  
286 using the Pathway Common database which contains directed interactions from a physical  
287 and pathways aspect. These new lists were then used for enrichment analysis  
288 (hypergeometric test) to identify enriched pathways from the REACTOME database.  
289 Enriched pathways were then represented in a heat map using log<sub>2</sub> z-scores. REACTOME  
290 database has a non-structured list of terms, therefore terms were clustered based on  
291 overlapping genes. All heat maps were produced with a heat map R package using  
292 Euclidean distances and hierarchical clustering. The same gene lists were used to test for  
293 enrichment in Gene Ontology cellular components and membrane-related terms were  
294 selected. Upstream regulator analysis was performed in Ingenuity Pathway Analysis (IPA).  
295 Venn diagrams were generated using <http://bioinformatics.psb.ugent.be/webtools/Venn/>.

296

297 *In vivo* data were processed with the same pipeline used for the *in vitro* experiments. Mapped reads  
298 ranged between 16M to 66M. Upregulated gene lists were produced and only genes with a log<sub>2</sub>  
299 FC>1 were used for further pathway analysis. Pathway analysis with REACTOME database was  
300 performed with InnateDB. TPM for all genes were obtained and transformed into log<sub>2</sub> scale. Quality  
301 control for 75 samples showed a batch effect due to two different labs sequencing the data. Combat  
302 function in the SVA R package was used<sup>44</sup> to reduce this effect. Principal component analysis  
303 identified an outlier that was removed for further analysis. Using the gene interactome lists for each  
304 strain from the *in vitro* data, a pan signature or module was obtained which included 200 genes that  
305 were upregulated in at least one strain. 16 genes were shared among all strains. Module scores for  
306 each group were derived by calculating the log<sub>2</sub> average gene expression for each module. A non-  
307 parametric (Mann-Whitney) test was performed to compare carriers to non-carriers for each time  
308 point. Violin plots were produced with in house script in R and ggplot2<sup>43</sup>.

309

## 310 **Statistics**

311 All experiments were conducted with replicates in three or more independent experiments  
312 unless stated otherwise. Error bars represent SEM unless stated otherwise. GraphPad  
313 Prism Version 10 was used to perform parametric (t-tests or ANOVA) or non-parametric  
314 (Mann-Whitney or Kruskal-Wallis tests) analysis, which was based on the Shapiro-Wilk  
315 normality test. P values lower than 0.05 were considered significant.

316

## 317 **RESULTS**

### 318 ***Streptococcus pneumoniae* colonisation of the human nasal mucosal is associated** 319 **with adhesion, microcolony formation and microinvasion**

320 We have used an Experimental Human Pneumococcal Carriage Model<sup>45</sup> to characterise  
321 pneumococcal-epithelial interactions *in vivo*. Colonisation was detected in 9/13 healthy  
322 volunteers by culture, 11/13 by microscopy and 9/11 by LytA PCR (Table 1). The carriage  
323 status of each volunteer in the study was blinded until sample collection was completed.

324 Differences in the results obtained with each detection method may reflect methodological  
325 threshold detection, or the location and therefore the accessibility of the colonising  
326 pneumococci (e.g. in the mucus escalator vs. adherence to the epithelial cell surface).  
327 Nonetheless, all three methods demonstrated that colonisation was established and that  
328 clearance largely occurred between day 9 and 27 (Table 1 and Figure 1B).

329

330 Curette biopsy samples yielded intact sheets of epithelial cell associated with immune cells  
331 visualised by confocal microscopy (Figure 1A and Supplementary Figure 1A).  
332 Pneumococcal surface adhesion increased over time and was associated with microcolony  
333 formation (Figure 1E, middle and right panels). This provides evidence that the EHPC model  
334 represents true carriage and colonisation of the pneumococci. There was also evidence of  
335 pneumococcal microinvasion through the epithelial monolayer (Figure 1C and 1D) which  
336 comprised both endocytosis (Figure 1E left and middle panels) and paracellular migration  
337 (Figure 1E, left panel). Internalised pneumococci were also observed in immune cells  
338 (Supplementary Figure 1A).

339

340 Co-association between pneumococci and the junctional protein JAM-A was also observed  
341 (Figure 1F). JAM-A is a tight junction protein which is important for the regulation of barrier  
342 function in the respiratory epithelium<sup>46</sup>. These bacteria were either located at junctions  
343 between cells (left panel) or internalised inside cells (right panel). Junctional association of  
344 *S. pneumoniae* were also observed with nasal epithelial cells grown in culture *ex-vivo*,  
345 differentiated on an air-liquid interface for 30 days and then co-cultured with either 6B or  
346 23F *S. pneumoniae* (Supplementary Figure 1B). Microcolony formation and internal  
347 pneumococci were also observed in these cell cultures.

348

349 **Epithelial surface marker expression in response to *Streptococcus pneumoniae* in**  
350 ***vivo***

351 We stained the nasal curette biopsies for surface expression of IL-22Ra1, HLADR, CD40,  
352 CD54 or CD107a. Epithelial cells were identified by EpCAM expression (Supplementary  
353 Figure 2A-D for Flow Cytometry parameters). IL-22Ra1 is expressed exclusively on  
354 epithelial cells<sup>47</sup> and is considered to protect the epithelial barrier and promote anti-microbial  
355 product secretion during infection, in response to IL-22 secretion by immune cells<sup>48,49</sup>. In  
356 the context of pneumococcal infection in mice, IL-22 appears to play an important role in  
357 carriage and clearance<sup>50,51</sup>. In the EHPC model, there was a trend towards increased  
358 expression of IL-22Ra1 at day 9, (when clearance starts to occur) in the carriage positive,  
359 compared to the carriage negative volunteers, although this did not reach statistical  
360 significance (Figure 2A, 2B top). We did not detect any change in the relative expression of  
361 inflammatory marker HLADR<sup>52</sup> on the nasal epithelium in carriers vs. non-carriers over time  
362 (Figure 2A, 2B, second row). Similarly, epithelial surface expression of CD40, a  
363 costimulatory protein which binds CD154 (CD40L) and CD54 (Intercellular Adhesion  
364 Molecule 1, ICAM-1) a key leukocyte adhesion molecule which is also upregulated by  
365 CD40<sup>53-55</sup>, and plays a role in neutrophil migration and recruitment<sup>56-59</sup>, did not change over  
366 time. Finally, we assessed the expression of CD107a, also known as lysosomal associated  
367 membrane protein 1 (LAMP-1) which is a marker for natural killer cell activity<sup>60</sup> and in the  
368 epithelium, forms the membrane glycoprotein of lysosomes and endosomes<sup>27</sup>. CD107a has  
369 been shown to be cleaved during infection with *Neisseria* species which are also  
370 extracellular mucosal pathogens<sup>61</sup>. Although the number of epithelial cells expressing  
371 CD107a did not change over time (Figure 2A, bottom), we did observe an increase intensity  
372 of expression at day 2 post inoculation in carriage positive volunteers vs. carriage negative  
373 volunteers, which was maintained throughout the remainder of the time course.

374

375 **Epithelial adherence, endocytosis and transmigration by *Streptococcus pneumoniae***  
376 **varies by pneumococcal strain and is modulated by pneumolysin**

377 To further investigate our observations from the EPHC, we undertook epithelial co-culture  
378 experiments with the cell line Detroit 562, derived from a nasal pharyngeal carcinoma. We  
379 used the EPHC 6B strain and two other representative clinical isolates serotype 4 (TIGR4,  
380 the original sequences strain) and 23F. Any differences between these strains are not simply  
381 explained by differential growth during colonisation (data not shown). Although they may be  
382 partially explained by capsule serotype<sup>37,62</sup>, TIGR4, 23F and 6B genome comparisons have  
383 revealed ~15,000 single nucleotide polymorphisms and insertion/deletion mutations (SNPs  
384 and INDELS) not related to capsule (data not shown). We have also used a TIGR4 strain  
385 where pneumolysin, a key virulence factor that is associated with pore-forming induced  
386 inflammation<sup>15,23</sup> has been knocked out (kind gift from Prof. TJ Mitchell, University of  
387 Birmingham, UK).

388

389 Strikingly, the number of TIGR4 pneumococci associated with the Detroit 562 cells was ten-  
390 fold higher than 6B or 23F strains (Figure 3A). This pattern was also observed by  
391 immunofluorescence (Figure 3D and 3E, and Supplementary Figure 4). Epithelial adhesion  
392 was associated with internalisation within the cells (Figure 3B) into what appeared to be  
393 intracellular vesicles that were coated in host proteins, in this case JAM-A (Figure 3G and  
394 Figure 5A), which indicates vesicular endocytosis and using bacteria that are pre-stained  
395 with FAMSE, we were able to distinguish extracellular bacteria (blue) from those below the  
396 apical surface prior to permeabilization of the cells (green, Figure 3F). Interestingly, co-  
397 association with another tight junction protein, Claudin 4, was not readily observed, while  
398 occasional co-association with the adherens junction protein  $\beta$  catenin was observed  
399 (Supplementary Figure 4A and 4B).

400 To assess transmigration, pneumococci that had penetrated the basal chamber of cells  
401 cultured on transwell inserts were counted. Although only statistically significant at 1hr  
402 between 23F and TIGR4, 23F was more readily detected compared to the other strains  
403 (Figure 3C). By microscopy, we observed laterally located bacteria, and pneumococci zip-  
404 wiring between cell junctions (Figure 3H). We observed pneumococci at the level of the  
405 nuclei and below the basal membrane (Figure 3I). This was more readily, but not exclusively,  
406 seen with the 23F strain. These data demonstrate a similar pattern of interaction between  
407 the *S. pneumoniae* 6B strain and human epithelium *in vivo* and *in vitro*; and show that the  
408 relative prominence of adhesion, endocytosis and paracellular transmigration varies by  
409 genotype.

410

411 Pneumolysin deletion in the TIGR4 mutant showed a significant increase in internalisation  
412 (Figure 3B) and an increase in transmigration capacity (Figure 3C). These data suggest that  
413 interactions within epithelial cells are in part, regulated by pneumolysin.

414

### 415 **Loss of epithelial cell barrier function is not a pre-requisite for microinvasion by *S.*** 416 ***pneumoniae***

417 Several mucosal pathogens including *S. pneumoniae*, are known to directly, and indirectly  
418 affect the integrity of epithelial barriers and tight junction function<sup>25,27,28,61,63-67</sup>. It was not  
419 possible to directly assess epithelial barrier function during colonisation in the EHPC model.  
420 We have therefore explored the possibility that over the same time frame where we have  
421 observed pneumococcal adhesion and microinvasion, epithelial surface molecule  
422 upregulation and cytokine production *in vitro*, there is epithelial barrier function disruption.  
423 Trans-epithelial electrical resistance (TEER) is not high in Detroit 562 cells but nevertheless  
424 TEER was not affected by pneumococcal co-culture (Figure 3J). To assess permeability,



425 4kDa FITC-dextran was applied to the apical chamber of transwells and epithelial leak  
426 quantified from the basal chamber. With the Detroit 562 cells, a significant reduction in  
427 permeability was seen with 6B pneumococci, 23F and TIGR4 (23 – 34%), compared to non-  
428 infected cells (Figure 3K). This implicates a role for pneumolysin in epithelial integrity.. These  
429 data suggest that loss of epithelial cell barrier function is not a pre-requisite for  
430 pneumococcal adhesion and microinvasion, and that as described in murine models<sup>23,25</sup>,  
431 changes to barrier function appear pneumolysin dependent.

432

433 To explore the possibility that our findings were not cell line dependent, we also used A549  
434 cells (Supplementary Figure 3A-E), which are undifferentiated alveolar Type II  
435 pneumocytes, and Calu3 cells (Supplementary Figure 3F-J), which represent a more  
436 polarised and differentiated cell originally derived from bronchial submucosa. Pneumococcal  
437 behaviour with both cell lines was similar, although absolute intensity of adhesion,  
438 microinvasion and transmigration differed (Supplementary Figure 3A and 3F,  
439 Supplementary Figure 3B and 3G, and Supplementary Figure 3C and 3H, respectively). This  
440 may in part be due to the high expression of polymeric Immunoglobulin Receptor found on  
441 Detroit cells<sup>63</sup>, and differential barrier function with A549 cells having the least trans-  
442 epithelial electrical resistance and the most permeability (Supplementary Figure 3D and 3E,  
443 respectively), and Calu3 having the greatest trans-epithelial electrical resistance and the  
444 least permeability (Supplementary Figure 3I and 3J, respectively). Importantly, no change  
445 in barrier function was seen with these cells. As with Detroit 562 cells, for A549 and Calu3  
446 cells TEER (Supplementary Figure DA and 3I) and permeability (Supplementary Figure 3E  
447 and 3J) was preserved following exposure to pneumococci for three hours. Indeed, if  
448 anything, epithelial co-culture resulted in an enhanced barrier function as shown via an  
449 increase in TEER (Supplementary Figure 3D) and a decrease in permeability to TIGR4  
450 (Supplementary Figure 3E) in A549 cells.

451 ***Streptococcus pneumoniae* upregulates epithelial surface CD54 and CD107a *in vitro***

452 It is uncertain whether the observed, at best, modest surface changes seen in the 6B EHPC  
453 model reflect a relatively silent host response to colonization by this strain, or was  
454 confounded by inter-volunteer variation. We have therefore compared the impact of the  
455 pneumococcal strains on Detroit 562 cell expression of the same range of surface markers.  
456 (See Supplementary Figure 2E-G for Flow Cytometry parameters). There was no significant  
457 change in epithelial markers IL-22Ra1, HLADR or CD40 (Figure 4A and 4B). However,  
458 although not seen with the 6B or 23F strains, CD54<sup>high</sup> expression was significantly greater  
459 for TIGR4 and dPLY strains, compared to non-infected cells. Epithelial CD107a, which has  
460 previously been implicated in pneumococcal endocytosis<sup>27</sup> was upregulated in response to  
461 the 6B, 23F and TIGR4 strains (Figure 4A and 4B, bottom graphs), but was not seen with  
462 the pneumolysin TIGR4 mutant. These data again demonstrate a similar pattern of  
463 interaction between the *S. pneumoniae* 6B strain and human epithelium *in vivo* and *in vitro*,  
464 *implicating* pneumolysin in the induction of CD54 but not CD107a surface expression.

465

466 ***S. pneumoniae* upregulates epithelial inflammatory cytokines and soluble CD54 *in***  
467 ***vitro***

468 To further investigate the inflammatory potential of the epithelium, measured for IL-6, IL-8  
469 and CD54 secretion in the supernatants of Detroit 562 cells following incubation with  
470 pneumococci (Figure 4C). We have detected a significant increase in IL-6 and IL-8 (P =  
471 <0.0001), which was not entirely pneumolysin dependent. In line with the surface marker  
472 observations, only TIGR4 significantly upregulated the secretion of soluble CD54 (P =  
473 0.0013), which was dependent on the presence of pneumolysin (Figure 4C). Other cytokine  
474 responses to *S. pneumoniae*, such as IFN $\gamma$ , IL-1 $\beta$  and TNF $\alpha$  were below the limits of  
475 detection (Data not shown).

## 476 **Internalised pneumococci do not replicate within the epithelium**

477 *S. pneumoniae* is generally considered to be an extracellular bacterium<sup>68</sup>. However, since  
478 we and others have observed intracellular bacteria<sup>27</sup>, we wanted to test whether they remain  
479 viable, can replicate, and egress from the epithelial cell. Pneumococci that adhere on the  
480 epithelial cell surface are capable of replicating, as demonstrated by epithelial surface  
481 microcolony formation in the 6B EHPC model (Figure 1E). In contrast, the pneumococci that  
482 were identified by confocal microscopy to be intracellular, were often single bacterial cells,  
483 co-localised with host proteins (Figure 5A) and did not appear to increase in number over  
484 time (Figure 5B). Bacteria that had transmigrated across the epithelial monolayer *in vitro* did  
485 replicate and remained viable for at least three hours post removal of the transwell insert  
486 (Figure 5C). To test the hypothesis that intracellular migration is not permissive for bacterial  
487 growth, we co-cultured pneumococci with epithelial cells for three hours, treated with  
488 gentamicin for one hour, replenished the media and recorded CFUs over time from the  
489 apical and basal chamber of transwell inserts (Figure 5D and E, respectively). Although  
490 bacteria were detected at low levels, replication was not readily apparent. To test whether  
491 these bacteria transmigrated across the cells in a transcellular or paracellular manner, we  
492 inhibited endocytosis by cellular treatment with Dynasore and Nystatin, or actin  
493 polymerisation by cellular treatment with Cytochalasin D. We found that the inhibition of  
494 endocytosis prevented transmigration but the inhibition of actin polymerisation enhanced  
495 transmigration in Detroit 562 cells with 23F pneumococci (data not shown).

496

## 497 ***Streptococcus pneumoniae* induces epithelial innate transcriptomic responses that** 498 **is influenced by the pattern of epithelial adhesion and microinvasion**

499 To further explore the hypothesis that the pattern of epithelial adhesion and microinvasion  
500 results in differential epithelial sensing and therefore epithelial inflammatory-response

501 genes, we performed RNAseq and obtained transcriptomic data from our pneumococci  
502 infected Detroit 562 cells. As shown in Figure 6A, we found that TIGR4 upregulated 1127  
503 genes (550 unique genes), 23F upregulated 650 genes (69 unique genes), and 6B  
504 upregulated only 153 genes (10 unique genes) compared to non-infected cells. The  
505 pneumolysin mutant upregulated 220 genes (14 unique genes). 93 genes were upregulated  
506 by all strains compared to non-infected cells. These findings appeared to reflect the invasive  
507 and inflammatory nature of these bacteria in this *in vitro* epithelial model. To further explore  
508 the nature of these differences, we performed pathway analyses using the REACTOME  
509 database and performed with XGR(Figure 6B). Again, we found that the upregulated  
510 pathways for TIGR4 and 23F were pro-inflammatory, but that the 6B profile was relatively  
511 silent. For example, TIGR4 upregulated pathways involved innate immunity, such as TLR  
512 signalling, cytokine signalling and stress responses. In comparison, 6B increased pathways  
513 involved in NOD and NRL signalling, and gene regulation. The TIGR4 pneumolysin mutant  
514 transcriptomic profile suggested that pneumolysin modulates epithelial cell RIG-I/MDA5  
515 mediated induction of IFN- $\alpha/\beta$  activation of IRF and NF $\kappa$ B pathways. In line with the cytokine  
516 profiles that we observed at the protein level, we detected upregulation of IL-6, IRAK2,  
517 TNFAIP3 and CD54 genes (Figure 6C) within the innate immune pathways selected  
518 (Supplementary Figure 5A). In line with our previous observation, 6B elicited the least and  
519 TIGR4 the greatest transcriptomic response. Given the pneumococcus interacts with the  
520 epithelial cell surface, analysis of genes associated with host cell membrane components  
521 were analysed at the transcriptomic level (Figure 6D) using Gene Ontology database  
522 (Cellular component terms only, Supplementary Figure 5B). Analysis of genes associated  
523 with host cell membrane components showed that the tight junction protein Claudin 4 was  
524 upregulated in response to 23F and TIGR4. Claudin 4 is normally associated with a tight  
525 barrier in epithelial cells<sup>69,70</sup>, which would support our hypothesis that the epithelium  
526 responds to preserve barrier function during co-culture.

527 Further bioinformatics analysis of upstream regulators revealed that RELA, or the nuclear  
528 factor NF $\kappa$ B p65 subunit is likely to be a key mediator of these pneumococcal-epithelial  
529 interactions (Figure 6E, Supplementary Figure 5C). Comparisons between the strains again  
530 reveal a more silent upstream profile with 6B compared to TIGR4 or 23F.

531

532 **Epithelial transcriptomic responses to *S. pneumoniae in vivo* are most marked**  
533 **around the time of bacterial clearance**

534 To test whether the relatively silent transcriptomic profile seen with the *S. pneumoniae* 6B  
535 strain during *in vitro* co-culture, was also present *in vivo*, we have first had to design an  
536 approach to focus on the epithelial response in the curette biopsy tissue. Using the *in vitro*  
537 epithelial transcriptomic data, we have derived an integrated transcriptome signature that  
538 allows us to interrogate the epithelial RNAseq transcriptomic response obtained from the 6B  
539 EHPC model (Supplementary Figure 6A). Within the cohort (Supplementary Figure 6B), the  
540 number of significantly upregulated genes was low (Figure 7A). However, looking at the  
541 genes average of the epithelial signatures' genes (200 genes for the Integrated and 16  
542 genes for the Core signature), we observed a shift in gene expression following 6B  
543 inoculation that was maximal at day 9, coinciding with the time of maximal bacterial  
544 clearance (Figure 7B, and Figure 7C, Integrated and Core signatures). Qualitatively, there  
545 was a shift from generic homeostasis at baseline towards a metabolic and innate defence  
546 profile at day 2, and surface receptor upregulation and inflammatory signalling pathways by  
547 day 9 (Figure 7A).

548

549

550

551 **DISCUSSION**

552 The upper respiratory tract is at the centre of the control of colonisation by a wide range of  
553 commensal bacteria. For some more pathogenic members of this commensal community,  
554 epithelial sensing and the triggering of inflammation may result in bacterial clearance but  
555 may also promote onward transmission. By combining *in vitro* cell culture systems and the  
556 EHPC model, we have shown that human epithelial sensing of the pneumococcus is  
557 enhanced by microinvasion, resulting in an epithelial inflammatory/innate immune response  
558 that is temporally associated with clearance.

559

560 We have demonstrated that the pneumococcus interacts with the human respiratory  
561 epithelium and that the innate epithelial cell response is dependent on the association of the  
562 bacteria (Figure 8). We show that colonisation leads to adherence, microcolony formation  
563 and microinvasion within the epithelium, which results in activation of signalling pathways  
564 that lead to cytokine and chemokine upregulation, biochemical and metabolic pathway  
565 enrichment. However, although microinvasion does not support bacterial growth, co-  
566 association with junctional proteins provides a possible mechanism for migration across the  
567 barrier, that could ultimately affect transmission or cause invasive disease. We provide  
568 evidence of epithelial sensing of the pneumococcus that coincides with clearance in the  
569 EHPC model.

570

571 The occurrence of microinvasion during colonisation in healthy individuals is supported by  
572 murine colonisation experiments<sup>71</sup> and the detection of pneumococcal DNA in the blood of  
573 healthy colonised children<sup>72</sup>. Using primary and immortalised epithelial cell line models that  
574 mirror this process, and in line with other cell culture and murine models<sup>64,66,71,73</sup>, we have  
575 demonstrated that pneumococcal microinvasion occurs by endocytosis and the formation of

576 cytoplasmic vacuoles, and by paracellular transcytosis. Transcriptomic analysis of the  
577 epithelial response *in vitro* and *in vivo* has revealed that the pattern of pneumococcal  
578 epithelial surface adherence and microinvasion determines the host cell response through  
579 a range of innate signalling and regulatory pathways, inflammatory mediators, adhesion  
580 molecules, cellular metabolism and stress response genes. These data support the view  
581 that beyond forming a physical barrier, secreting mucus, and modulating the transport of  
582 immunoglobulins, the epithelium plays a critical role in the regulation of these complex host-  
583 pathogen interactions<sup>19,74,75</sup>.

584

585 Nasal colonisation in murine models is proinflammatory<sup>24,76</sup> and is associated with epithelial  
586 microinvasion and tight junction modulation<sup>25</sup>. Our *in vitro* epithelial model co-culture with a  
587 serotype 6B strain suggests that this is not always the case with only modest pneumococcal-  
588 host cell adherence, endocytosis and paracellular migration, and a relatively silent epithelial  
589 inflammatory profile. Indeed, volunteers who undergo EHPC generally remain clinically  
590 asymptomatic and this silent transcriptomic pattern of epithelial response is mirrored in the  
591 6B EHPC model, where we have observed surface adherence, microcolony formation and  
592 some microinvasion.

593

594 After three hours infection *in vitro*, we did not observe a breakdown of epithelial barrier  
595 function. Previous studies in mice and human lung tissue that have investigated infection  
596 over longer periods of incubation, have seen tight junction dysregulation<sup>25,64</sup>, and we did  
597 observe co-association with junctional proteins such as JAM-A and  $\beta$  catenin. IN accordance  
598 with studies in human alveolar cells<sup>64</sup>, Claudin 4 was not affected by the pneumococcus,  
599 although we did detect a transcriptomic upregulation in Detroit cells. In mice, changes in  
600 claudin regulation was TLR dependent<sup>25,77</sup> and we detected TLR4 and TLR3 activation in

601 our Detroit 562 cells transcriptomic analyses, in response to all strains of the pneumococci  
602 we tested. Previous studies have implicated pneumolysin to activate TLR2 and TLR4  
603 stimulated cytokine release, such as IL-6 and IL-8, both of which we detected in infected  
604 Detroit 562 cell supernatants<sup>30,78</sup>. Interestingly, TLR3 is normally associated with double  
605 stranded RNA detection of viruses, such as Influenza<sup>79</sup>. There appears to be a relationship  
606 between the outcome of infection between Influenza and *S. pneumoniae*<sup>79,80</sup>, which may be  
607 important for understanding the dynamics of flu vaccination success. TLR3 leads to the  
608 activation of IRF3 and the secretion of type 1 interferons<sup>81,82</sup>. Type 1 interferons have been  
609 shown to be stimulated in response to murine pneumococcal infection that leads to bacterial  
610 clearance<sup>83,84</sup>. Here, the authors also show anti-microbial product secretion, and we  
611 detected evidence of  $\beta$  defensin gene upregulation in the EHPC model two days post  
612 inoculation with 6B (Figure 7A). We also detected upregulation of RIG-I/MDA5 mediated  
613 induction of IFN- $\alpha/\beta$  pathways following *in vitro* stimulation with the TIGR4 pneumolysin  
614 mutant, providing further evidence that sensing by the epithelium may be important. DNA  
615 sensing of *S. pneumoniae* has been demonstrated in alveolar macrophages, where  
616 secretion of Type 1 Interferons led to upregulation of STING and the transcription factor IFN  
617 regulatory factor 3, augmented by pneumolysin<sup>76,84</sup>.

618

619 Pneumolysin, a pore forming toxin, has been implicated as a major virulence factor  
620 contributing to host inflammation and transmission<sup>23,85</sup>. We found pneumolysin to be a  
621 prominent trigger of epithelial surface molecule upregulation, cytokine production and the  
622 transcriptomic inflammatory response *in vitro*. The prominence of TLR4 signalling pathways  
623 in the transcriptomic profile observed and the presence of TLR4 on epithelial cells,  
624 implicates pneumolysin. Mediated by autolysin, the pneumococcus undergoes autolysis  
625 when reaching stationery growth phase, resulting in the release of additional PAMPs  
626 including bacterial DNA. We therefore suggest that in the context of microinvasion,



627 pneumococcal DNA may act as an alternative epithelial sensing agonist to induce  
628 inflammation. Furthermore, cellular entry of DNA may be enhanced by pneumolysin pore  
629 formation<sup>84</sup>. In mice, pneumococcal DNA triggers inflammation through a  
630 DAI/STING/TBK1/IRF3 cascade<sup>76,84</sup>, a response that contributes to pneumococcal  
631 clearance. Indeed, we observed an increased epithelial expression of the lysosomal  
632 membrane protein CD107a, following pneumococcal co-infection.

633

634 Our findings are limited by the number of pneumococcal strains that can be safely tested in  
635 an EHPC model to enable direct comparisons between the *in vivo* and *in vitro* data.  
636 Nonetheless, the use of different strains *in vitro* has enabled us and others<sup>73,86</sup> to interrogate  
637 the impact of different patterns of epithelial adherence and invasion on the host  
638 inflammatory/ innate immune response. Transcriptomic analysis has enabled us to postulate  
639 the potential epithelial sensing pathways but these will need to be fully defined in more  
640 precise model systems. We have placed considerable reliance on the findings from  
641 immortalised cell lines from relevant tissue but our findings have been reassuringly  
642 paralleled by our findings in primary cell lines derived from the EHPC and the EHPC itself.

643

644 Our data highlight the complex interactions between the host epithelium and *S. pneumoniae*  
645 whereby pneumococcal microinvasion may ultimately dictate the outcome of colonisation,  
646 altering the delicate balance between inflammation-mediated transmission and clearance  
647 (Figure 8). Ultimately, epithelial sensing of pneumococcal-epithelial interaction and its  
648 outcome may be dictated by the bacterial strain, the force of infection, or the frequency of  
649 co-colonisation of pneumococcal strains, (more important in children and high carriage  
650 prevalence populations), viral co-infections and other environmental pressures<sup>1,20,87</sup>.  
651 Measures of human to human transmission are needed to fully understand the critical

652 pathways and a mechanistic insight into the impact of pneumococcal vaccine on epithelial  
653 adhesion and invasion is required if we are to improve herd protection.

654

## 655 **Acknowledgements**

656 This study was funded by the Wellcome Trust (Grant 106846/Z/15/Z). DF is supported by  
657 the Medical Research Council (grant MR/M011569/1), Bill and Melinda Gates Foundation  
658 (grant OPP1117728) and the National Institute for Health Research (NIHR) Local  
659 Comprehensive Research Network. LytA PCR was performed by Prof. D Bogaert, University  
660 of Edinburgh, UK. RNAseq library preparation undertaken at UCL was provided by the  
661 Pathogens Genomic Unit. Confocal imaging facilities at LSTM were funded by a Wellcome  
662 Trust Multi-User Equipment Grant (104936/Z/14/Z). Flow cytometric acquisition was funded  
663 by a Wellcome Trust Multi-User Equipment Grant (104936/Z/14/Z).

664

665 **Author contributions:** CMW, SPJ, DMF and RSH conceived and designed the study.  
666 CMW, SP, SPJ, JR, EN, CS, CA acquired the data. CMW, CV, SPJ, MN, JSB, DMF, RSH  
667 analysed and interpreted the data. CMW wrote the first draft of the manuscript. CMW, CV,  
668 SP, SPJ, JR, EN, CS, CA, MN, JSB, DMF, RSH commented on and approved the  
669 manuscript.

670

671 **Conflicts of interest:** the authors declare no conflicts of interest.

672

673

674 **REFERENCES**

675

676

- 677 1. O'Brien, K.L., *et al.* Burden of disease caused by *Streptococcus pneumoniae* in children younger  
678 than 5 years: global estimates. *Lancet* **374**, 893-902 (2009).
- 679 2. Kagnoff, M.F. The intestinal epithelium is an integral component of a communications network. *J*  
680 *Clin Invest* **124**, 2841-2843 (2014).
- 681 3. Jochems, S.P., Weiser, J.N., Malley, R. & Ferreira, D.M. The immunological mechanisms that  
682 control pneumococcal carriage. *PLoS Pathog* **13**, e1006665 (2017).
- 683 4. Shiri, T., *et al.* Indirect effects of childhood pneumococcal conjugate vaccination on invasive  
684 pneumococcal disease: a systematic review and meta-analysis. *Lancet Glob Health* **5**, e51-e59  
685 (2017).
- 686 5. Whitney, C.G., *et al.* Decline in invasive pneumococcal disease after the introduction of protein-  
687 polysaccharide conjugate vaccine. *N Engl J Med* **348**, 1737-1746 (2003).
- 688 6. Usuf, E., Bottomley, C., Adegbola, R.A. & Hall, A. Pneumococcal carriage in sub-Saharan Africa-  
689 -a systematic review. *PLoS One* **9**, e85001 (2014).
- 690 7. Brueggemann, A.B., Pai, R., Crook, D.W. & Beall, B. Vaccine escape recombinants emerge after  
691 pneumococcal vaccination in the United States. *PLoS Pathog* **3**, e168 (2007).
- 692 8. Hanage, W.P., *et al.* Carried pneumococci in Massachusetts children: the contribution of clonal  
693 expansion and serotype switching. *Pediatr Infect Dis J* **30**, 302-308 (2011).
- 694 9. Pillai, D.R., *et al.* Genome-wide dissection of globally emergent multi-drug resistant serotype 19A  
695 *Streptococcus pneumoniae*. *BMC Genomics* **10**, 642 (2009).
- 696 10. Mosser, J.F., *et al.* Nasopharyngeal carriage and transmission of *Streptococcus pneumoniae* in  
697 American Indian households after a decade of pneumococcal conjugate vaccine use. *PLoS One* **9**,  
698 e79578 (2014).
- 699 11. Pido-Lopez, J., Kwok, W.W., Mitchell, T.J., Heyderman, R.S. & Williams, N.A. Acquisition of  
700 pneumococci specific effector and regulatory Cd4+ T cells localising within human upper respiratory-  
701 tract mucosal lymphoid tissue. *PLoS Pathog* **7**, e1002396 (2011).
- 702 12. Glennie, S.J., *et al.* Regulation of Naturally Acquired Mucosal Immunity to *Streptococcus*  
703 *pneumoniae* in Healthy Malawian Adults and Children. *PLoS One* **7**, e51425 (2012).
- 704 13. Zhang, Q., *et al.* Characterisation of regulatory T cells in nasal associated lymphoid tissue in  
705 children: relationships with pneumococcal colonization. *PLoS Pathog* **7**, e1002175 (2011).
- 706 14. Lipsitch, M., *et al.* Are Anticapsular Antibodies the Primary Mechanism of Protection against  
707 Invasive Pneumococcal Disease? *PLoS Med* **2**, e15 (2005).
- 708 15. Ratner, A.J., *et al.* Epithelial cells are sensitive detectors of bacterial pore-forming toxins. *J Biol*  
709 *Chem* **281**, 12994-12998 (2006).

- 710 16. Ratner, A.J., Lysenko, E.S., Paul, M.N. & Weiser, J.N. Synergistic proinflammatory responses  
711 induced by polymicrobial colonization of epithelial surfaces. *Proc Natl Acad Sci U S A* **102**, 3429-  
712 3434 (2005).
- 713 17. Eisele, N.A. & Anderson, D.M. Host Defense and the Airway Epithelium: Frontline Responses  
714 That Protect against Bacterial Invasion and Pneumonia. *J Pathog* **2011**, 249802 (2011).
- 715 18. Ganesan, S., Comstock, A.T. & Sajjan, U.S. Barrier function of airway tract epithelium. *Tissue*  
716 *Barriers* **1**, e24997 (2013).
- 717 19. Whitsett, J.A. & Alenghat, T. Respiratory epithelial cells orchestrate pulmonary innate immunity.  
718 *Nat Immunol* **16**, 27-35 (2015).
- 719 20. Plotkowski, M.C., Puchelle, E., Beck, G., Jacquot, J. & Hannoun, C. Adherence of type I  
720 Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus. *Am*  
721 *Rev Respir Dis* **134**, 1040-1044 (1986).
- 722 21. Pittet, L.A., Hall-Stoodley, L., Rutkowski, M.R. & Harmsen, A.G. Influenza virus infection  
723 decreases tracheal mucociliary velocity and clearance of Streptococcus pneumoniae. *Am J Respir*  
724 *Cell Mol Biol* **42**, 450-460 (2010).
- 725 22. McCullers, J.A., Iverson, A.R., McKeon, R. & Murray, P.J. The platelet activating factor receptor  
726 is not required for exacerbation of bacterial pneumonia following influenza. *Scand J Infect Dis* **40**,  
727 11-17 (2008).
- 728 23. Zafar, M.A., Wang, Y., Hamaguchi, S. & Weiser, J.N. Host-to-Host Transmission of  
729 Streptococcus pneumoniae Is Driven by Its Inflammatory Toxin, Pneumolysin. *Cell Host Microbe* **21**,  
730 73-83 (2017).
- 731 24. Wilson, R., *et al.* Protection against Streptococcus pneumoniae lung infection after  
732 nasopharyngeal colonization requires both humoral and cellular immune responses. *Mucosal*  
733 *Immunol* **8**, 627-639 (2015).
- 734 25. Clarke, T.B., Francella, N., Huegel, A. & Weiser, J.N. Invasive bacterial pathogens exploit TLR-  
735 mediated downregulation of tight junction components to facilitate translocation across the  
736 epithelium. *Cell Host Microbe* **9**, 404-414 (2011).
- 737 26. Agarwal, V., Asmat, T.M., Dierdorf, N.I., Hauck, C.R. & Hammerschmidt, S. Polymeric  
738 immunoglobulin receptor-mediated invasion of Streptococcus pneumoniae into host cells requires a  
739 coordinate signaling of SRC family of protein-tyrosine kinases, ERK, and c-Jun N-terminal kinase. *J*  
740 *Biol Chem* **285**, 35615-35623 (2010).
- 741 27. Asmat, T.M., Agarwal, V., Saleh, M. & Hammerschmidt, S. Endocytosis of Streptococcus  
742 pneumoniae via the polymeric immunoglobulin receptor of epithelial cells relies on clathrin and  
743 caveolin dependent mechanisms. *Int J Med Microbiol* **304**, 1233-1246 (2014).
- 744 28. Beisswenger, C., Coyne, C.B., Shchepetov, M. & Weiser, J.N. Role of p38 MAP kinase and  
745 transforming growth factor-beta signaling in transepithelial migration of invasive bacterial pathogens.  
746 *J Biol Chem* **282**, 28700-28708 (2007).

- 747 29. Ratner, A.J., Aguilar, J.L., Shchepetov, M., Lysenko, E.S. & Weiser, J.N. Nod1 mediates  
748 cytoplasmic sensing of combinations of extracellular bacteria. *Cell Microbiol* **9**, 1343-1351 (2007).
- 749 30. Malley, R., *et al.* Recognition of pneumolysin by Toll-like receptor 4 confers resistance to  
750 pneumococcal infection. *Proc Natl Acad Sci U S A* **100**, 1966-1971 (2003).
- 751 31. Gewirtz, A.T., Navas, T.A., Lyons, S., Godowski, P.J. & Madara, J.L. Cutting edge: bacterial  
752 flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene  
753 expression. *J Immunol* **167**, 1882-1885 (2001).
- 754 32. Gewirtz, A.T., *et al.* Salmonella typhimurium translocates flagellin across intestinal epithelia,  
755 inducing a proinflammatory response. *J Clin Invest* **107**, 99-109 (2001).
- 756 33. Hornef, M.W., Wick, M.J., Rhen, M. & Normark, S. Bacterial strategies for overcoming host  
757 innate and adaptive immune responses. *Nat Immunol* **3**, 1033-1040 (2002).
- 758 34. Ferreira, D.M., *et al.* Controlled human infection and rechallenge with Streptococcus  
759 pneumoniae reveals the protective efficacy of carriage in healthy adults. *Am J Respir Crit Care Med*  
760 **187**, 855-864 (2013).
- 761 35. Browall, S., *et al.* Intraclonal variations among Streptococcus pneumoniae isolates influence the  
762 likelihood of invasive disease in children. *J Infect Dis* **209**, 377-388 (2014).
- 763 36. McCool, T.L., Cate, T.R., Moy, G. & Weiser, J.N. The immune response to pneumococcal  
764 proteins during experimental human carriage. *J Exp Med* **195**, 359-365 (2002).
- 765 37. Hyams, C., Camberlein, E., Cohen, J.M., Bax, K. & Brown, J.S. The Streptococcus pneumoniae  
766 capsule inhibits complement activity and neutrophil phagocytosis by multiple mechanisms. *Infect*  
767 *Immun* **78**, 704-715 (2010).
- 768 38. Collins, A.M., *et al.* First human challenge testing of a pneumococcal vaccine. Double-blind  
769 randomized controlled trial. *Am J Respir Crit Care Med* **192**, 853-858 (2015).
- 770 39. Jochems, S.P., *et al.* Novel Analysis of Immune Cells from Nasal Microbiopsy Demonstrates  
771 Reliable, Reproducible Data for Immune Populations, and Superior Cytokine Detection Compared  
772 to Nasal Wash. *PLoS One* **12**, e0169805 (2017).
- 773 40. Bray, N.L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq  
774 quantification. *Nat Biotechnol* **34**, 525-527 (2016).
- 775 41. Sonesson, C., Love, M.I. & Robinson, M.D. Differential analyses for RNA-seq: transcript-level  
776 estimates improve gene-level inferences. *F1000Res* **4**, 1521 (2015).
- 777 42. Varet, H., Brillet-Gueguen, L., Coppee, J.Y. & Dillies, M.A. SARTools: A DESeq2- and EdgeR-  
778 Based R Pipeline for Comprehensive Differential Analysis of RNA-Seq Data. *PLoS One* **11**,  
779 e0157022 (2016).
- 780 43. Fang, H., Knezevic, B., Burnham, K.L. & Knight, J.C. XGR software for enhanced interpretation  
781 of genomic summary data, illustrated by application to immunological traits. *Genome Med* **8**, 129  
782 (2016).
- 783 44. Chakraborty, S., Datta, S. & Datta, S. Surrogate variable analysis using partial least squares  
784 (SVA-PLS) in gene expression studies. *Bioinformatics* **28**, 799-806 (2012).

- 785 45. Wright, A.K., *et al.* Human nasal challenge with *Streptococcus pneumoniae* is immunising in the  
786 absence of carriage. *PLoS Pathog* **8**, e1002622 (2012).
- 787 46. Mitchell, L.A., *et al.* Junctional adhesion molecule A promotes epithelial tight junction assembly  
788 to augment lung barrier function. *Am J Pathol* **185**, 372-386 (2015).
- 789 47. Wolk, K., *et al.* IL-22 increases the innate immunity of tissues. *Immunity* **21**, 241-254 (2004).
- 790 48. Pham, T.A., *et al.* Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization  
791 resistance to an opportunistic pathogen. *Cell Host Microbe* **16**, 504-516 (2014).
- 792 49. Zheng, M., *et al.* Therapeutic Role of Interleukin 22 in Experimental Intra-abdominal *Klebsiella*  
793 *pneumoniae* Infection in Mice. *Infect Immun* **84**, 782-789 (2016).
- 794 50. Van Maele, L., *et al.* Activation of Type 3 innate lymphoid cells and interleukin 22 secretion in  
795 the lungs during *Streptococcus pneumoniae* infection. *J Infect Dis* **210**, 493-503 (2014).
- 796 51. Trevejo-Nunez, G., Elsegeiny, W., Conboy, P., Chen, K. & Kolls, J.K. Critical Role of IL-22/IL22-  
797 RA1 Signaling in Pneumococcal Pneumonia. *J Immunol* **197**, 1877-1883 (2016).
- 798 52. Fais, S., *et al.* HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: I.  
799 Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of  
800 other surface markers. *Clin Exp Immunol* **68**, 605-612 (1987).
- 801 53. Propst, S.M., Denson, R., Rothstein, E., Estell, K. & Schwiebert, L.M. Proinflammatory and Th2-  
802 derived cytokines modulate CD40-mediated expression of inflammatory mediators in airway  
803 epithelia: implications for the role of epithelial CD40 in airway inflammation. *J Immunol* **165**, 2214-  
804 2221 (2000).
- 805 54. Dugger, K., Lowder, T.W., Tucker, T.A. & Schwiebert, L.M. Epithelial cells as immune effector  
806 cells: the role of CD40. *Semin Immunol* **21**, 289-292 (2009).
- 807 55. Cagnoni, F., *et al.* CD40 on adult human airway epithelial cells: expression and proinflammatory  
808 effects. *J Immunol* **172**, 3205-3214 (2004).
- 809 56. Huang, G.T., Eckmann, L., Savidge, T.C. & Kagnoff, M.F. Infection of human intestinal epithelial  
810 cells with invasive bacteria upregulates apical intercellular adhesion molecule-1 (ICAM)-1  
811 expression and neutrophil adhesion. *J Clin Invest* **98**, 572-583 (1996).
- 812 57. Bianco, A., *et al.* Expression of intercellular adhesion molecule-1 (ICAM-1) in nasal epithelial  
813 cells of atopic subjects: a mechanism for increased rhinovirus infection? *Clin Exp Immunol* **121**, 339-  
814 345 (2000).
- 815 58. Sumagin, R., *et al.* Neutrophil interactions with epithelial-expressed ICAM-1 enhances intestinal  
816 mucosal wound healing. *Mucosal Immunol* **9**, 1151-1162 (2016).
- 817 59. Frick, A.G., *et al.* *Haemophilus influenzae* stimulates ICAM-1 expression on respiratory epithelial  
818 cells. *J Immunol* **164**, 4185-4196 (2000).
- 819 60. Alter, G., Malenfant, J.M. & Altfeld, M. CD107a as a functional marker for the identification of  
820 natural killer cell activity. *J Immunol Methods* **294**, 15-22 (2004).
- 821 61. Lin, L., *et al.* The *Neisseria* type 2 IgA1 protease cleaves LAMP1 and promotes survival of  
822 bacteria within epithelial cells. *Mol Microbiol* **24**, 1083-1094 (1997).

- 823 62. Aprianto, R., Slager, J., Holsappel, S. & Veening, J.W. Time-resolved dual RNA-seq reveals  
824 extensive rewiring of lung epithelial and pneumococcal transcriptomes during early infection.  
825 *Genome Biol* **17**, 198 (2016).
- 826 63. Zhang, J.R., *et al.* The polymeric immunoglobulin receptor translocates pneumococci across  
827 human nasopharyngeal epithelial cells. *Cell* **102**, 827-837 (2000).
- 828 64. Peter, A., *et al.* Localization and pneumococcal alteration of junction proteins in the human  
829 alveolar-capillary compartment. *Histochem Cell Biol* **147**, 707-719 (2017).
- 830 65. Coyne, C.B. The distinct roles of JAM-A in reovirus pathogenesis. *Cell Host Microbe* **5**, 3-5  
831 (2009).
- 832 66. Short, K.R., *et al.* Influenza virus damages the alveolar barrier by disrupting epithelial cell tight  
833 junctions. *Eur Respir J* **47**, 954-966 (2016).
- 834 67. Weight, C.M., Jones, E.J., Horn, N., Wellner, N. & Carding, S.R. Elucidating pathways of  
835 *Toxoplasma gondii* invasion in the gastrointestinal tract: involvement of the tight junction protein  
836 occludin. *Microbes Infect* **17**, 698-709 (2015).
- 837 68. Henriques-Normark, B. & Tuomanen, E.I. The pneumococcus: epidemiology, microbiology, and  
838 pathogenesis. *Cold Spring Harb Perspect Med* **3**(2013).
- 839 69. Mitchell, L.A., Overgaard, C.E., Ward, C., Margulies, S.S. & Koval, M. Differential effects of  
840 claudin-3 and claudin-4 on alveolar epithelial barrier function. *Am J Physiol Lung Cell Mol Physiol*  
841 **301**, L40-49 (2011).
- 842 70. Rokkam, D., Lafemina, M.J., Lee, J.W., Matthay, M.A. & Frank, J.A. Claudin-4 levels are  
843 associated with intact alveolar fluid clearance in human lungs. *Am J Pathol* **179**, 1081-1087 (2011).
- 844 71. Mahdi, L.K., Ogunniyi, A.D., LeMessurier, K.S. & Paton, J.C. Pneumococcal virulence gene  
845 expression and host cytokine profiles during pathogenesis of invasive disease. *Infect Immun* **76**,  
846 646-657 (2008).
- 847 72. Morpeth, S.C., *et al.* Detection of Pneumococcal DNA in Blood by Polymerase Chain Reaction  
848 for Diagnosing Pneumococcal Pneumonia in Young Children From Low- and Middle-Income  
849 Countries. *Clin Infect Dis* **64**, S347-S356 (2017).
- 850 73. Bootsma, H.J., Egmont-Petersen, M. & Hermans, P.W. Analysis of the in vitro transcriptional  
851 response of human pharyngeal epithelial cells to adherent *Streptococcus pneumoniae*: evidence for  
852 a distinct response to encapsulated strains. *Infect Immun* **75**, 5489-5499 (2007).
- 853 74. Zanin, M., Baviskar, P., Webster, R. & Webby, R. The Interaction between Respiratory  
854 Pathogens and Mucus. *Cell Host Microbe* **19**, 159-168 (2016).
- 855 75. Vareille, M., Kieninger, E., Edwards, M.R. & Regamey, N. The airway epithelium: soldier in the  
856 fight against respiratory viruses. *Clin Microbiol Rev* **24**, 210-229 (2011).
- 857 76. Koppe, U., *et al.* *Streptococcus pneumoniae* stimulates a STING- and IFN regulatory factor 3-  
858 dependent type I IFN production in macrophages, which regulates RANTES production in  
859 macrophages, cocultured alveolar epithelial cells, and mouse lungs. *J Immunol* **188**, 811-817 (2012).

- 860 77. Beisswenger, C., Lysenko, E.S. & Weiser, J.N. Early bacterial colonization induces toll-like  
861 receptor-dependent transforming growth factor beta signaling in the epithelium. *Infect Immun* **77**,  
862 2212-2220 (2009).
- 863 78. Schmeck, B., *et al.* Pneumococci induced TLR- and Rac1-dependent NF-kappaB-recruitment  
864 to the IL-8 promoter in lung epithelial cells. *Am J Physiol Lung Cell Mol Physiol* **290**, L730-L737  
865 (2006).
- 866 79. Spelmink, L., *et al.* Toll-Like Receptor 3/TRIF-Dependent IL-12p70 Secretion Mediated by  
867 *Streptococcus pneumoniae* RNA and Its Priming by Influenza A Virus Coinfection in Human Dendritic  
868 Cells. *MBio* **7**, e00168-00116 (2016).
- 869 80. Rudd, J.M., Ashar, H.K., Chow, V.T. & Teluguakula, N. Lethal Synergism between Influenza  
870 and *Streptococcus pneumoniae*. *J Infect Pulm Dis* **2**(2016).
- 871 81. Chen, N., *et al.* RNA sensors of the innate immune system and their detection of pathogens.  
872 *IUBMB Life* **69**, 297-304 (2017).
- 873 82. Alexopoulou, L., Holt, A.C., Medzhitov, R. & Flavell, R.A. Recognition of double-stranded RNA  
874 and activation of NF-kappaB by Toll-like receptor 3. *Nature* **413**, 732-738 (2001).
- 875 83. Joyce, E.A., Popper, S.J. & Falkow, S. *Streptococcus pneumoniae* nasopharyngeal colonization  
876 induces type I interferons and interferon-induced gene expression. *BMC Genomics* **10**, 404 (2009).
- 877 84. Parker, D., *et al.* *Streptococcus pneumoniae* DNA initiates type I interferon signaling in the  
878 respiratory tract. *MBio* **2**, e00016-00011 (2011).
- 879 85. Hotomi, M., Yuasa, J., Briles, D.E. & Yamanaka, N. Pneumolysin plays a key role at the initial  
880 step of establishing pneumococcal nasal colonization. *Folia Microbiol (Praha)* **61**, 375-383 (2016).
- 881 86. Novick, S., *et al.* Adhesion and invasion of *Streptococcus pneumoniae* to primary and secondary  
882 respiratory epithelial cells. *Mol Med Rep* **15**, 65-74 (2017).
- 883 87. Glennie, S.J., Williams, N.A. & Heyderman, R.S. Mucosal immunity in resource-limited setting:  
884 is the battle ground different? *Trends Microbiol* **18**, 487-493 (2010).

885

886

887

888

889

890



891 **FIGURE LEGENDS**

892 **Table 1. *Streptococcus pneumoniae* association with the nasal epithelium in the**  
893 **EHPC model detected by culture, confocal microscopy and LytA PCR**

894 Nasal washes and nasal curette biopsies were collected from carriage positive and carriage  
895 negative volunteers over time. Standard methods for measuring bacterial density by culture  
896 (CFU) and LytA PCR were compared against counts visualised by confocal microscopy for  
897 pneumococcal association with nasal cells over time. The data was derived from 13  
898 volunteers. + (1-10 pneumococci); ++ (11-50 pneumococci); +++ (51-100 pneumococci);  
899 +++++ (>100 pneumococci) ND = not done.

900

901 **Figure 1. *Streptococcus pneumoniae* colonisation of the human nasal epithelium is**  
902 **associated with adhesion, microcolony formation and microinvasion**

903 (A) Nasal curette biopsies were processed from the EHPC model. Images show  
904 representative fields demonstrating that areas of intact epithelium can be obtained from the  
905 samples (as visualised by XY planes) and they retain their size and shape (as visualised by  
906 XZ planes). Cells were stained with Wheat Germ Agglutinin (WGA) or JAM-A (red) and  
907 nuclei (blue). (B) Graphical representation of the pattern of pneumococcal density detected  
908 by culture and microscopy. (C) The proportion of bacteria located on the cell surface,  
909 intracellularly, or paracellularly visualized by confocal microscopy, quantified from 8  
910 volunteers collected over time. Data is derived from microscopy counts. The cells were  
911 stained for surface carbohydrates using WGA, and the bacteria were marked with specific  
912 serotype antiserum. (D) XY images of 1µm slices through a layer of cells, with bacteria  
913 associated. XY image of cells showing (Ei) bacterial internalization, (Eii) and microcolony  
914 formation on the surface of an epithelial cell, with one intracellular bacterium. (Eiii) XZ and  
915 YZ stacks demonstrating surface association of single and multiple bacteria per cell (top),

916 possible migration through the epithelium either internally or between cells (middle), and  
917 residing at or below the level of the cell nuclei (bottom). (F) Co-association between *S.*  
918 *pneumoniae* (green) and JAM-A (red). Nuclei (blue). Internalised bacteria were also  
919 observed to be co-associated with JAM-A.

920

921 **Figure 2. Epithelial surface marker expression in response to *Streptococcus***  
922 ***pneumoniae in vivo* analysed by flow cytometry**

923 (A) Median fluorescence intensity for IL-22Ra, HLADR, CD40, CD54 or CD107a. (B) High  
924 surface marker-expressing cells (>95% of the baseline expression). Results are from a  
925 minimum of two volunteers. Black squares are carriage negative and grey circles are  
926 carriage positive. There were no significant differences in surface marker expression  
927 between the carriage positive and negative samples.

928

929 **Figure 3. Epithelial adherence, endocytosis and transmigration by *Streptococcus***  
930 ***pneumoniae*, the influence of pneumolysin and the impact on barrier function**

931 Detroit 562 cell monolayers (approximately  $1 \times 10^6$  per well) were stimulated with  $7 \times 10^6$   
932 pneumococci  $\pm 2.75 \times 10^6$  for 3 hours and the quantity of bacteria (A) associated with the  
933 cells, and (B) internalized inside the cells, were determined by culture (CFU). N = >6  
934 independent experiments with replicates. \*\*\*\* P = <0.0001. (C) Detroit 562 cells cultured on  
935 transwell inserts were stimulated with approximately  $1.2 \times 10^7$  pneumococci  $\pm 6 \times 10^6$  for 3  
936 hours and the quantity of bacteria in the basal chamber was determined over time. P values  
937 at 0.5hr = 0.1751; 1hr, \* P = 0.0187; 2hr, P = 0.1222; 3hr, P = 0.0740. N = 5 independent  
938 experiments with replicates. (D) Representative pneumococcal-density images of Detroit  
939 562 cells following three hours infection. (E-I) Representative images illustrating differences  
940 in association between strains on epithelial cells stained with JAM-A. (E) Difference in

941 surface density of pneumococci between 6B and TIGR4; (F) apical association of bacteria  
942 (extracellular blue) and green (below the level of the apical surface,), co-association with  
943 JAM-A; (G) internalisation of bacteria as shown in JAM-A associated intracellular vesicle-  
944 like bodies; (H) lateral localisation of the pneumococci (top) with possible paracellular  
945 movement across the monolayer (bottom); (I) basal localisation of bacteria both at the nuclei  
946 level and the transwell insert pore level. Images are representative of examples across all  
947 experiments (n = >20) and across Detroit 562 cells, Calu3 cells and A549 cells.

948

949 Detroit 562 cells were exposed with pneumococci for three hours on transwell inserts and  
950 TEER and permeability were recorded. (K) The average TEER for these cells was  $19\Omega\cdot\text{cm}^2$   
951 ( $\pm 15\Omega\cdot\text{cm}^2$ , data not shown). ANOVA shows a significant effect from calcium withdrawal \*\*\*  
952  $P = 0.0013$  (n = 3). There was no difference in TEER between non-infected and  
953 pneumococcal-infected cells,  $P = 0.6334$ . n = 9 independent experiments with replicates. (J)  
954 Permeability was assessed by leak to 4kDa FITC-dextran. N = >4 independent experiments.  
955 \*\*\*\*  $P = <0.0001$  comparing non-infected against pneumococcal strains.

956

957 **Figure 4. Modulation of epithelial surface molecule expression, cytokine and soluble**  
958 **CD54 secretion by *Streptococcus pneumoniae* in vitro**

959 (A) Monolayers of Detroit 562 cells were stimulated with *S. pneumoniae* for 6 hours and the  
960 median fluorescence intensity for each epithelial activation marker was analysed by flow  
961 cytometry. (B) High-expressing cells for each marker were compared against non-infected  
962 cells, which were set at 5%. n = >3 independent experiments. \*  $P < 0.05$  CD54; \*\*\*\*  $P <$   
963  $0.0001$  CD107a median and \*\*\*  $P < 0.001$  CD107a 5%, all comparing non-infected to strains  
964 of pneumococci (except median CD107a, TIGR4 v dPLY where  $P = 0.0009$  and 5% CD107a,  
965 TIGR4 v dPLY where  $P = 0.0286$ ). (C) IL-6, IL-8 and CD54 in the supernatants from Detroit

966 562 cells stimulated with *S. pneumoniae* for 6 hours were measured by ELISA. Results  
967 represent six independent experiments with replicates. \*\*\*\* P <0.0001 IL-6; \*\*\* P = 0.0013  
968 CD54; \*\*\*\* P < 0.0001 IL-8).

969

## 970 **Figure 5. Pneumococci internalised within the epithelium do not replicate**

971 (A) Representative images of internalised pneumococci co-localised with JAM-A as  
972 indicated by the arrows (B) A549 cells were incubated with *S. pneumoniae* for three hours,  
973 washed, treated with gentamicin for 1 hour, and the cultures were incubated for further time  
974 points to measure bacterial internalisation (B). Data represents three independent  
975 experiments with replicates. \*\*\*\* P = <0.0001. (C) Detroit 562 cells were incubated with  
976 pneumococci for three hours on transwell inserts which were then removed and bacteria in  
977 the basal chamber were further incubated in the absence of cells. (n = 5 for three hours, n  
978 = 2 for 4 hours, n = 1 for 5 hours (latter error bars S.D)). (D and E) Detroit 562 cells were  
979 incubated with *S.pneumoniae* for three hours, washed, treated with gentamicin for one hour,  
980 washed, and bacteria that were released into the apical (D) or basal (E) chamber were  
981 counted. N = 3 independent experiments with replicates. Similar results were also observed  
982 with Calu 3 cells (data not shown).

983

## 984 **Figure 6. *Streptococcus pneumoniae* induces epithelial innate transcriptomic** 985 **responses *in vitro* that are influenced by the pattern of epithelial adhesion and** 986 **microinvasion**

987 (A) The total number of epithelial genes upregulated following exposure to 6B, 23F, TIGR4  
988 and TIGR4-dPLY pneumococci, compared to non-infected samples. Genes with an FDR  
989 <0.05 were considered for further analysis. The matrix shows intersections for the four

990 strains, sorted by size. Dark circles in the matrix indicates sets that are part of the  
991 intersection. (B) Clustered heat map representing the log<sub>2</sub> zeta scores of REACTOME  
992 Pathway Analysis of epithelial cells exposed to pneumococci. For clarity, only pathways with  
993 a p-value of 0.001 are represented. Clustered heat maps representing the log<sub>2</sub> fold-  
994 changes for genes of pathways involved in (C) innate immunity and (D) membrane  
995 components. Genes that are not upregulated (I.E. where the FDR is above 0.05 and not in  
996 the interactome) are coloured in light grey. (E) Using the upstream regulator analysis in IPA,  
997 transcription regulators with an activated Z-score greater than 2, were compared following  
998 exposure to each strain of pneumococci. The 20-most activated epithelial transcription  
999 regulators are shown in the table.

1000

1001 **Figure 7. Epithelial transcriptomic responses to *Streptococcus pneumoniae* in the**  
1002 **EHPC model are most marked around the time of bacterial clearance**

1003 (A) The overlap of upregulated genes between time points and significant REACTOME  
1004 pathways. (B) Log<sub>2</sub> TPM arithmetic mean for genes in the integrated interactome module.  
1005 (C) Log<sub>2</sub> TPM arithmetic mean for genes in the core interactome module. RNA from nasal  
1006 curette biopsies was used to identify genes that were upregulated with a log<sub>2</sub> fold-change  
1007 of  $\geq 1$  were compared between baseline (day minus 4) and 2 and 9 days post inoculation of  
1008 6B in the EHPC model. Epithelial modules were generated from the *in vitro* epithelial RNA  
1009 data.

1010

1011

1012

1013 **Figure 8. Model of the control of pneumococcal colonisation by the human mucosal**  
1014 **epithelium.**

1015 Following pneumococcal adhesion and microcolony formation on the epithelial surface, the  
1016 host response is dependent on the subsequent pattern of interaction. Microinvasion  
1017 (endocytosis and paracellular transmigration) amplifies epithelial sensing and inflammation/  
1018 innate immunity, which we postulate leads to immune cell engagement. This process of  
1019 epithelial sensing inflammation/ innate immunity may enhance both transmission and  
1020 clearance. Co-association with junctional proteins may facilitate migration across the barrier.

1021


1022

1023

Table 1

| Vol | Microbiology density (CFU/ml) |                     |                     |                     |      | Microscopy counts |     |      |    |     | LytA PCR |       |       |       |        | Association |               |         |
|-----|-------------------------------|---------------------|---------------------|---------------------|------|-------------------|-----|------|----|-----|----------|-------|-------|-------|--------|-------------|---------------|---------|
|     | Pre                           | D2                  | D6                  | D9                  | D27  | Pre               | D2  | D6   | D9 | D27 | Pre      | Day 2 | Day 6 | Day 9 | Day 27 | Surface     | Intracellular | Lateral |
| 1   | 0                             | 370                 | 520                 | 10                  | 1.6  | 0                 | +   | +    | 0  | +   | NEG      | POS   | POS   | ND    | POS    | +           | 0             | 0       |
| 2   | 0                             | 0                   | 0                   | 0                   | 0    | 0                 | +   | 0    | 0  | 0   | NEG      | NEG   | NEG   | ND    | NEG    | ++          | +             | 0       |
| 3   | 0                             | 0                   | 0                   | 0                   | 0    | 0                 | +   | +    | 0  | 0   | NEG      | POS   | NEG   | ND    | NEG    | +           | 0             | 0       |
| 4   | 0                             | 2.8                 | 8.8                 | 0                   | 0    | 0                 | 0   | 0    | +  | 0   | NEG      | POS   | POS   | ND    | NEG    | +           | 0             | 0       |
| 5   | 0                             | 7x10 <sup>3</sup>   | 220                 | 21                  | 0    | 0                 | +   | +    | +  | 0   | ND       | ND    | ND    | ND    | ND     | +           | +             | 0       |
| 6   | 0                             | 1.9x10 <sup>4</sup> | 5.7x10 <sup>3</sup> | 3.7x10 <sup>4</sup> | 11   | 0                 | ++  | ++++ | ++ | 0   | NEG      | POS   | POS   | ND    | POS    | +++         | ++            | +       |
| 7   | 0                             | 820                 | 1.1x10 <sup>3</sup> | 160                 | 0    | 0                 | +   | +++  | ++ | 0   | NEG      | POS   | POS   | ND    | NEG    | ++          | +             | +       |
| 8   | 0                             | 0                   | 0                   | 0                   | 0    | 0                 | 0   | 0    | 0  | +   | ND       | ND    | ND    | ND    | ND     | 0           | 0             | 0       |
| 9   | 0                             | 220                 | 700                 | 3.8                 | 0.04 | ND                | +   | +++  | +  | ND  | NEG      | POS   | POS   | ND    | NEG    | +++         | +             | +       |
| 10  | 0                             | 1x10 <sup>3</sup>   | 0.04                | 0.04                | 0    | ND                | 0   | +    | 0  | ND  | NEG      | POS   | POS   | ND    | POS    | +           | 0             | 0       |
| 11  | 0                             | 1.8x10 <sup>6</sup> | 1.8x10 <sup>6</sup> | 1.9x10 <sup>4</sup> | 0.08 | ND                | +++ | ++++ | +  | ND  | NEG      | POS   | POS   | ND    | NEG    | +++         | +             | +       |
| 12  | 0                             | 0                   | 0                   | 0                   | 0    | ND                | ++  | 0    | 0  | ND  | NEG      | NEG   | NEG   | ND    | NEG    | ++          | +             | +       |
| 13  | 0                             | 23                  | 1.7                 | 0                   | 0    | ND                | +   | 0    | 0  | ND  | POS      | POS   | POS   | ND    | POS    | +           | 0             | 0       |

Figure 1





bioRxiv preprint doi: <https://doi.org/10.1101/281576>; this version posted July 12, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

No reuse allowed without permission.




Figure 2






**Figure 4**




bioRxiv preprint doi: <https://doi.org/10.1101/281576>; this version posted March 13, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

# Figure 5


**A**




**B**



**C**



**D**



**E**






Figure 6




bioRxiv preprint doi: <https://doi.org/10.1101/281576>; this version posted March 13, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

Figure 7

A



B



C




Figure 8

